Dr. John R. Evans is a retired physician, businessperson, public servant, academic and an active corporate director. He is currently chair of the board of directors of the MaRS Centre and a member of the boards of directors of several Canadian corporations.

Following five years as a member of the Department of Medicine at the University of Toronto and physician at Toronto General Hospital, he was appointed as founding dean of the McMaster University Faculty of Medicine in Hamilton. He served as President of the University of Toronto from 1972 to 1978 and as director of the Department of Population, Health and Nutrition Development of the World Bank in Washington. He returned to Toronto in 1983 as Chairman and CEO and Allelix Inc., a biotechnology research company and remains vice-chair of the merged company, NPS Bio-pharmaceuticals Inc. He has served as chair of Torstar, which publishes the Toronto Star, Alcan, the Walter and Duncan Gordon Charitable Foundation, the Board of Trustees of the Rockefeller Foundation, the Global Stewardship Initiative of the of the Pew Charitable Trusts and the Institute for Clinical Evaluative Studies.

Dr. Evans received his undergraduate training in medicine from the University of Toronto and his specialty training in internal medicine and cardiology in London, England. He is a member of the Order of Ontario, a Companion of the Order of Canada and recipient of innumerable awards recognizing outstanding public service.

Dr. Elizabeth Eisenhauer

Dr. Elizabeth Eisenhauer is a senior scientist who is interested in the evaluation of new anti-cancer agents. As director of the Investigational New Drug Program of the National Cancer Institute of Canada (NCIC) Clinical Trials Group since 1982, her major responsibilities involve bringing novel cancer agents to clinical trials. She is also a professor in the Department of Oncology at Queen’s University in Kingston and maintains a small practice in medical oncology at the Kingston Regional Cancer Centre.

Eisenhauer has been a member of the provincial committees for developing treatment guidelines for melanoma and gynecologic cancer, human resources planning for oncology professionals, and new cancer research initiatives for government investment in Canada. She has served for many years on the Research Advisory Panel of Cancer Care Ontario, the provincial agency that organizes cancer care delivery.  Eisenhauer has also has served on numerous NCIC grants panels and a committee of the Royal College of Physicians and Surgeons of Canada on clinical investigation. She served for several years on the US National Cancer Institute (NCI) Cancer Clinical Investigation Review Committee and in 1997 chaired a Clinical Trials Advisory Committee of the NCI’s Intramural Clinical Research Program that led to many modifications in the infrastructure of the NCI’s research efforts.

Eisenhauer obtained her MD from Queen’s University in 1976 and subsequently completed Royal College of Physicians and Surgeons (Canada) training in both internal medicine and hematology. In 1998 she was the Michel Clavel Award lecturer at the NCI-EORTC Symposium on New Drugs in Cancer Treatment held in Amsterdam. In 2002 she was awarded the O. Harold Warwick Prize by the NCIC, which recognizes a scientist whose research has had a major impact in Cancer Control in Canada. In 2002 she was appointed to the board of directors of the NCIC and in 2004 was elected as the organization’s vice- president.

Dr. Peter George

Dr. Peter George is a well-known scholar and educator with extensive experience in senior academic administrative and executive positions. He has served as vice-chancellor of McMaster University since July of 1995. As president of McMaster, Dr. George is responsible for the academic and fiscal direction of one of Canada’s leading research universities, with annual budgeted expenditures exceeding $690 million in 2005-2006. The University has some 18,000 full-time and 2,900 part-time undergraduate students, 2,500 full-and part-time graduate students, and more than 3,500 faculty and staff. More than 110,000 McMaster alumni live in 125 countries around the world.

George joined McMaster University’s faculty in 1965 and was promoted to full professorship in 1980. He has served as associate dean of graduate studies, dean of the Faculty of Social Sciences and as President of the Council of Ontario Universities. During his initial term as president of McMaster, George led and implemented a strategic planning initiative called Directions, which continues in renewed form as Refining Directions, to guide the University’s development of the innovative teaching and research programs. He successfully led the recent Changing Tomorrow Today fundraising campaign that surpassed its $100 million target, raising over $128 million from the private sector, and leveraging close to $400 million in new resources for the University.

George received his PhD in Economics from the University of Toronto. A Member of the Order of Canada, George has received many awards for innovative educational leadership and community activities. He is currently a board member of the Royal Botanical Gardens, St. Joseph’s Hospital, the Institute for Work and Health, the C.D. Howe Institute, and the Golden Key International Honour Society, among others. He has earned a strong reputation for his forthright views on higher education and its contributions to economic and social renewal, and continues to write and speak on issues in the management and impact of higher education.

Dr. Jack Kitts

Dr. Jack Kitts has been president and CEO of The Ottawa Hospital since February 2002. He previously served as the large, multi-site hospital’s vice-president, medical affairs, starting in 1998.

From 1981 to 1984, he served as a medical officer in the Canadian Forces. Dr. Kitts joined the Department of Anesthesiology at the Ottawa Civic Hospital (merged into the newly created Ottawa Hospital in 1998) in 1988 and was appointed chief of the department in 1995. In 1996, he was appointed associate professor of Anesthesia at the University of Ottawa.

Dr. Kitts graduated from the Faculty of Medicine, University of Ottawa, in 1980 and completed his internship at the University of Toronto in 1981. He completed a Masters of Business Administration from the University of Ottawa in 2001.

Mark Lievonen

Mark Lievonen is president of Aventis Pasteur Limited, the leading provider of vaccines in Canada. He has been with the company since 1983.

Prior to his appointment as president, Lievonen served as senior vice-president and general manager of the oncology business unit. In 2004, he was appointed to the board of directors of Calgary-based Oncolytics Biotech Inc., a research firm. He is also a member of the board of directors of BIOTECanada and served as Chair from 2000 to 2003.

Lievnonen also has a strong interest in public sector research. He has been a member of the board of directors of the Ontario Genomics Institute since 2002 and was appointed chair in 2004.

John Morrison

John Morrison is a retired chief executive and corporate director of leading companies and voluntary organizations. He has been responsible for operations in Canada, the U.S., Europe and Asia, and for customers in over 60 countries. He has experience dealing with Health Canada and equivalent regulators in the U.S., Europe and Japan.

Morrison served as group president, health care at MDS Inc. from 2003-2005, and in other positions at MDS from 1991. He previously served as president and CEO of Laidlaw Waste Systems and for two divisions of Toronto-based CCL Industries, and prior to that in a variety of roles at Continental Can Canada leading up to terms as chair, president and CEO.

Morrison graduated from the University of New Brunswick with a Bachelor of Science in mechanical engineering. His volunteer experience includes membership on the boards of directors of Shad International, which operates a science program for gifted children. He is the former vice-chair of the University of Guelph Board of Governors.

Dr. Christopher Paige

Dr. Christopher Paige is vice-president, research of the University Health Network, which oversees the Toronto General Hospital, Toronto Western Hospital and Princess Margaret Hospital. He is also a professor in the departments of Medical Biophysics and Immunology and Ronald Buick Chair in Cancer Research at the University of Toronto. He is an active educator in the undergraduate, graduate and postgraduate programs of the University’s medical school and is a sought after speaker at science and medical conferences worldwide.

Paige began his career as a member of the Basel Institute for Immunology in Switzerland where he worked from 1980-1987 before joining the Ontario Cancer Institute as a senior scientist in 1987.  In 1990, Dr. Paige became the founding director of the Arthritis and Autoimmunity Research Centre as well as director of research at the Wellesley Hospital in Toronto. In 1998, Paige returned to the Ontario Cancer Institute and subsequently assumed his current position at the University of Toronto. He is an internationally recognized leader in the area of lymphocyte development and antibody formation.  He is the principal investigator in a Terry Fox Program Project on blood cell development and his research has been supported for many years by the Canadian Institutes of Health Research and the National Cancer Institute of Canada.  His original research is published in leading scientific journals. He has served on the Advisory Boards of the National Cancer Institute and the Arthritis Society of Canada.

Dr. Paige earned a Ph.D. in Immunology at the Sloan-Kettering Division of Cornell University Graduate School of Medical Sciences in 1979. Dr. Paige is the Chairman of Board of the Toronto Biotechnology Commercialization Center, a biotechnology incubator developed in partnership with the MaRS Centre and the Toronto Academic Health Sciences Network.  He is also chair of BioDiscovery Toronto, one of Ontario’s Regional Innovation Networks, designed to provide a coordinated “storefront” for the research business development offices of the hospitals and universities in the Greater Toronto Area.

Dr. David Parkinson

Dr. David R. Parkinson was recently appointed president and CEO of Nodality Inc., a research company working on patient-specific treatments. He was previously senior vice-president, oncology research and development of the San Diego-based biotechnology firm Biogen Idec. In this role, he oversaw all oncology discovery research efforts and the development of the oncology pipeline. During his tenure at Biogen Idec and in his previous position as senior vice-president, oncology development at Amgen, he was been responsible for clinical development activities leading to a series of global drug registrations for important cancer therapeutics.

Dr. Parkinson worked at the National Cancer Institute from 1990 to 1997, serving as chief of the Investigational Drug Board, then as acting associate director of the Cancer Therapy Evaluation Program before leaving for a position at Novartis. He had previously also held academic positions at the M.D. Anderson Cancer Center, University of Texas and New England Medical Center, Tufts University School of Medicine. Currently, Dr. Parkinson serves on the National Cancer Policy Forum of the Institute of Medicine and a member of the U.S. Food and Drug Administration’s Science Board. He was recently elected to the board for directors of the American Association of Cancer Research (AACR) and is the chair of its finance committee.

Parkinson received his MD from the University of Toronto Faculty of Medicine in 1977 and internal medicine and hematology/oncology training in Montreal at McGill University and then in Boston at New England Medical Center. He is a past Chairman of the FDA Biologics Advisory Committee and is a recipient of the FDA’s Cody Medal.

Graham W.S. Scott

Graham W.S. Scott is a senior partner at Toronto law firm McMillan Binch Mendelsohn. He leads the public policy and government issues practice, with a focus on health care issues. He serves as chair of the board of the Canadian Institute for Health Information and as a director on several boards, including that of pharmaceutical company Sanofi Pasteur.

Scott has extensive experience in governance in the voluntary sector and in the assessment of boards and management teams in both the voluntary and public sectors. A lawyer since 1968, Scott has served as associate secretary of the cabinet, deputy minister of environment and deputy minister of health.

Scott graduated from the University of Western of Ontario with a BA in 1965 and an LLB in 1966. His many honours include the Order of Canada and an appointment as co-chair of the Prime Minister’s Advisory Committee on Government Restructuring and membership in its successor organization, the Advisory Committee on Public Service.

Dr. Calvin Stiller

Dr. Calvin Stiller is a lifelong innovator whose work encompasses science, business and public service. As a scientist, Stiller was principal investigator on the Canadian multi-centre study that established the effectiveness of Cyclosporine in transplantation, which led to its worldwide use as first-line therapy for transplant rejection. He has published 265 scientific and medical papers, co-edited five books and authored Lifegifts, a book about organ transplantation.

In 1985 Dr. Stiller established the Multi-Organ Transplant Service in London and served as its chief for over a decade. He has been president of the Canadian Society of Nephrology and co-founded the MaRS Centre, the J. Allyn Taylor International Prize in Medicine and the Canadian Medical Hall of Fame. Dr. Stiller is also an entrepreneur and businessperson. He founded two firms that eventually employed 4,000 people in health care and technology services, which were later sold and taken public. He established four venture capital funds to invest in innovation, including the largest life sciences fund in Canada. He has also founded three companies that have provided seed funding for 50 technologies and created over a quarter of a billion dollars in economic activity.

Stiller received his medical degree from the University of Saskatchewan in 1965 and his fellowship in the Royal College of Physicians and Surgeons of Canada (FRCPC) in 1975 following seven years of post-graduate studies in Edmonton and London, Ontario. He is a member of the Order of Ontario and the Order of Canada and the recipient of Honorary Degrees from the University of Saskatchewan, McMaster University and the University of Western Ontario.

Dr. Terry Sullivan

Dr. Terry Sullivan has been with Cancer Care Ontario since 2001, when he joined the provincial cancer agency as a leader in preventive oncology research. He is currently the agency’s president and CEO. He holds appointments in the departments of Health Policy Management and Evaluation and Public Health Sciences at the University of Toronto.

From 1993 to 2001, Sullivan was president of the Institute for Work and Health (IWH), a private not-for-profit institute affiliated with the University of Toronto which he developed into North America’s leading research centre on work-related injury. He has played senior roles in the Ontario Ministries of Health, Intergovernmental Affairs and the Cabinet Office.  He served as assistant deputy minister, constitutional affairs and federal provincial relations, during the Charlottetown Accord negotiations and served two successive Ontario premiers as executive director of the Premier's Council on Health Strategy and as a deputy minister.

Pamela Wallin

Pamela Wallin is the senior advisor to the president of the Americas Society and the
Council of the Americas in New York, chancellor of the University of Guelph and a director on several corporate boards, including CTVglobemedia, which publishes the Globe and Mail. She offers her time and experience to various educational, medical and cultural organizations as well as many other volunteer groups. From 2002 to 2006, she served as Canadian Consul in New York.

Over the course of her career in journalism, Wallin worked for the CBC, the Toronto Star and CTV television network, where she hosted Canada AM and later served as Ottawa bureau chief. In 1992 she became the first Canadian woman to co-anchor the nightly national television newscast Prime Time News. In 1995, she founded her own television production company and produced nightly interview program. The focus of much of Wallin’s reporting has been Canada’s relationship with the United States.

Wallin has been awarded thirteen honorary doctorates. She has been inducted into the Canadian Broadcasting Hall of Fame, was the Distinguished Honoree of the Canadian Society of New York, and has been recognized twice by Queen Elizabeth II for her public service and achievements.